These provisions set forth the refund conditions and procedures for "BioRev PRO" (the "Service") provided by BioRev Inc. (the "Company").
Article 1 (Scope)
These provisions apply to users of the Service ("Users").
These provisions shall be construed integrally with the Service Agreement and the disclosures based on the Specified Commercial Transactions Act.
Article 2 (Purpose of the Refund Program)
The refund program provides a refund of the product price when, despite the User satisfying the prescribed conditions, no defined result is confirmed under the evaluation criteria established by the Company.
This program does not guarantee any efficacy or effect.
Article 3 (Eligibility)
This refund program applies only to Users who use the Service within Japan.
Overseas residents and test data obtained outside Japan are not eligible.
Article 4 (Refund Conditions)
A User may apply for a refund only if all of the following conditions are met.
- Resides in Japan
- Has completed the initial payment for the Service (JPY 600,000)
- Has undergone testing at a medical institution or testing facility recognized by the Company within Japan prior to use
- Has used the Service for 10 days in accordance with the dosage, instructions, and Company directions
- Has completed all check-ins for the 10 days
- Has undergone re-testing at a testing facility within Japan under the same or equivalent conditions after use
- Has submitted the pre- and post-use test data (originals or official copies)
- No improvement is confirmed under the evaluation criteria established by the Company
Article 5 (Evaluation Criteria)
- The Company will evaluate the submitted test data based on its own evaluation criteria.
- The specific content of the evaluation criteria is determined at the Company's discretion and may not be individually disclosed to Users.
- If the testing methods, items, or measurement conditions do not match, accurate comparison may not be possible and the case may not be eligible for refund.
Article 6 (Refundable Amount)
Refunds are limited to the product price for the Service (initial payment of JPY 600,000).
The following costs are not refundable.
- Testing fees
- Transportation expenses
- Communication expenses
- Bank fees
- Other incidental expenses
Article 7 (Refund Application)
- Users shall apply for refunds by the method specified by the Company.
- The following information must be submitted at the time of application.
- (1) Pre-use test data
- (2) Post-use test data
- (3) Testing facility information
- (4) Identity verification information
- (5) Bank account information for refund
- (6) Other information deemed necessary by the Company
- Applications must be submitted within 14 days of the re-test date.
Article 8 (Review and Refund)
- The Company will review the submitted information and data.
- Review typically takes 7 to 30 days.
- If the Company determines a refund is warranted, it will issue the refund to the designated account.
- The method and timing of the refund are determined by the Company.
Article 9 (Non-Refundable Cases)
Refunds will not be issued in the following cases.
- Overseas residents
- Test data obtained outside Japan
- Incomplete check-ins
- Violation of dosage or instructions
- Mismatched testing conditions
- Significant changes in physician treatment or medication
- Significant lifestyle changes
- False statements or fraudulent applications
- Incomplete documentation
- Cases the Company deems inappropriate
Article 10 (Fraudulent Acts)
If a User makes a false application, falsifies data, or obtains a refund through fraudulent means, the Company may refuse the refund and take legal action as necessary.
Article 11 (Disclaimer)
- The Service is not a medical practice.
- The Service does not replace diagnosis, treatment, or prescription by a physician.
- The Company does not guarantee improvement of health conditions or cure of diseases.
- This refund program does not guarantee results.
Article 12 (Changes to Provisions)
The Company may change these provisions as necessary.
Article 13 (Governing Law and Jurisdiction)
These provisions are governed by Japanese law, and the court having jurisdiction over the location of the Company shall have exclusive jurisdiction by agreement over any disputes.
End
Established: April 1, 2026
BioRev Inc.
Representative Director, CEO
Mina Yoshizaki